CN105343675A - 一种治疗肥胖症的中药制剂及其制备方法 - Google Patents
一种治疗肥胖症的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN105343675A CN105343675A CN201510904037.1A CN201510904037A CN105343675A CN 105343675 A CN105343675 A CN 105343675A CN 201510904037 A CN201510904037 A CN 201510904037A CN 105343675 A CN105343675 A CN 105343675A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine preparation
- parts
- caulis spatholobi
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 208000008589 Obesity Diseases 0.000 title claims abstract description 45
- 235000020824 obesity Nutrition 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000012567 medical material Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 19
- 241000180649 Panax notoginseng Species 0.000 claims description 17
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 241000244155 Taenia Species 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003390 Chinese drug Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 210000002784 stomach Anatomy 0.000 abstract description 14
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000029087 digestion Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 2
- 230000002040 relaxant effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 235000013291 Alisma plantago aquatica Nutrition 0.000 abstract 1
- 240000004615 Alisma plantago-aquatica Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003925 fat Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 235000021251 pulses Nutrition 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 240000004580 Magnolia hypoleuca Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000521581 Millettia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010271 massa medicata fermentata Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药技术领域,公开了一种治疗肥胖症的中药制剂及其制备方法,该中药制剂的中药组方由下述重量配方的中药制备而成:鸡血藤10-20、丹参10-24、青皮10-22、荷叶12-22、川芎10-20、泽泻10-22、厚朴8-16、三七8-14、当归8-12、枳壳6-12、山楂10-14、薏苡仁12-16和甘草2-10。本发明中药制剂组方采用天然中药,其组分简单、配方合理、毒副作用小、使用方便,具有利尿泄热、润肠通便、下气除满、消食健胃等功效,可安全、有效治疗肥胖症。
Description
技术领域
本发明属于中药技术领域,尤其涉及一种治疗肥胖症的中药制剂及其制备方法。
背景技术
肥胖症又名肥胖病,由于日常食物摄入过多或机体代谢的改变而导致体内脂肪积聚过多,造成体重过度增长,并引起人体病理生理的改变,是一种多因素慢性代谢性疾病。肥胖症多无无明确病因,大多数学者认为是过量的能量摄入和静止型的生活方式(运动不足)所致;少数人认为,与食物过量摄入、家庭遗传、生理和心理疾病、个人不良的生活习惯等有关。总而言之,能量的过量摄入大于消耗是肥胖的成因。现如今肥胖症患者越来越多,由此带来的疾病危害也随之增多。肥胖可以引发多种疾病,如高血压,冠心病、心绞痛、脑血管疾病、糖尿病、高脂血症、高尿酸血症、女性月经不调等,还能增加恶性肿瘤的患病率。
目前常用的治疗肥胖症的西药主要有两类:一种是作用于中枢的食欲抑制剂,又称厌食性药物,它是通过影响神经递质的活性,减少5-羟色胺和去甲肾上腺素再摄取,从而减少食物摄入量,抑制食欲和提高基础代谢率来减重,如西布曲明;另一种是作用于外周的脂肪酶抑制剂,即通过阻断饮食中部分脂肪的吸收达到减肥目的,如奥利司他。但两者都有比较明显的不良反应,限制了这些药物用于长期维持治疗。
依中医理论的整体观念,从脏腑辩证分析肥胖主要与肾、脾、肝三脏的功能有关,以脾肾气虚为多见,肝胆疏泄失调也可见。治病必求其本。肥胖者既有本虚证,又有标实证,本虚以气虚为主,标实以膏脂、痰浊为主。抓住本虚标实,通过中药合理配伍可以达到调理脏腑,使肝、脾、肾之功能恢复正常,通过调节饮食结构,预防外界脂肪摄入过剩、改善身体内环境,让身体本身具备消耗多余脂肪的能力,这才是治疗肥胖症的根本途径。
中国发明专利申请201410007923.X涉及到一种治疗肥胖症的中药组合物,该中药组合物包括以下制备原料:茯苓、半夏、苍术、香附、陈皮、神曲、川芎和牵牛子。对肥胖症的治疗起效快,副作用小,但用药上仅考虑肥胖症本身,未充分考虑到肥胖症的伴生病症,比如高血压、高血脂等,因此不易根除病症。
发明内容
治疗肥胖症的同时应充分考虑到高血压、高血脂、高血糖等伴生病症。因此。本发明的目的为全面用药,充分考虑到肥胖症的伴生病症,辨证治疗,药到病除。
为实现本发明的目的,本发明技术方案如下:
本发明中药制剂的中药组方中各药材重量配方为:
鸡血藤10-20、丹参10-24、青皮10-22、荷叶12-22、川芎10-20、泽泻10-22、厚朴8-16、三七8-14、当归8-12、枳壳6-12、山楂10-14、薏苡仁12-16和甘草2-10。
在该配方范围内,优选了3个疗效较为显著的配方:
配方1:鸡血藤10、丹参10、青皮10、荷叶12、川芎10、泽泻10、厚朴8、三七8、当归8、枳壳6、山楂10、薏苡仁12和甘草2。
配方2:鸡血藤20、丹参24、青皮22、荷叶22、川芎20、泽泻22、厚朴16、三七14、当归12、枳壳12、山楂14、薏苡仁16和甘草10。
配方3:鸡血藤15、丹参18、青皮16、荷叶16、川芎14、泽泻16、厚朴12、三七10、当归10、枳壳10、山楂12、薏苡仁14和甘草6。
相应地,本发明还提供所述中药制剂的制备方法,包括以下步骤:
S1:取鸡血藤,洗去杂质,干燥后粉碎,过80-100目筛,加入药材总重量8-10倍量体积分数为60-80%的乙醇,再加入药材总量0.8-1.2%的纤维素酶,在38-45℃下浸提1-2小时,然后在85-95℃回流提取3-5小时,过滤并保留鸡血藤滤渣,滤液减压浓缩至60℃下相对密度为1.10-1.25的浸膏,制得鸡血藤提取物;
S2、分别称取丹参、青皮、荷叶、当归、枳壳、竹茹、山楂、薏苡仁和甘草,粉碎,混合,加入8-11倍药材重量的纯化水,煎煮2-3次,每次3-5小时,过滤,合并滤液,浓缩为原体积的1/6-1/4,获得提取液A,备用;
S3、分别称取三七、川芎、厚朴和泽泻,粉碎,混合,合并鸡血藤滤渣,加4-7倍药材重量70-90%的乙醇,回流提取2-3次,每次3-6小时,合并醇提液,减压蒸馏,除去乙醇,获得提取液B,备用;
S4、将鸡血藤提取物、提取液A和提取液B混合,浓缩至70-80℃时相对密度为1.25-1.36的中药浸膏,喷雾干燥,过100-200目筛,即得。
本发明中药组方所用中药材的来源、性味、归经及功效:
鸡血藤:本品为豆科崖豆藤属的植物,味苦、甘,性温;归肝、肾经;补血,活血,通络;活血舒筋,养血调经。
丹参:本品为唇形科植物丹参的干燥根及根茎;味苦,性微寒;归心、肝经;祛瘀止痛,活血通经,清心除烦。
青皮:本品为芸香科植物橘及其栽培变种的干燥幼果或未成熟果实的果皮;味苦、辛,性温;归肝、胆、胃经;疏肝破气,消积化滞。
荷叶:本品为睡莲科植物莲的干燥叶;味苦,性平;归肝、脾、胃经;清热解暑,升发清阳,凉血止血。
川芎:本品为伞形科植物川芎的干燥根茎;味辛,性温;归肝、胆、心包经;活血行气,祛风止痛。
泽泻:本品为泽泻科植物泽泻的干燥块茎;味甘,性寒;归肾、膀胱经;利小便,清湿热。
厚朴:本品为木兰科植物厚朴或凹叶厚朴的干燥干皮、根皮及枝皮;味苦、辛,性温;归脾、胃、肺、大肠经;燥湿消痰,下气除满。
三七:本品为五加科植物三七的干燥根;味甘、微苦,性温;归肝、胃经;散瘀止血,消肿定痛。
当归:本品为伞形科植物当归的干燥根;味甘、辛,性温;归肝、心、脾经;补血活血,调经止痛,润肠通便。
枳壳:本品为芸香科植物酸橙及其栽培变种的干燥未成熟果实;味苦、辛、酸,性温;归脾、胃经;理气宽中,行滞消胀。
山楂:本品为蔷薇科植物山里红或山楂的干燥成熟果实;味酸、甘,性微温;归脾、胃、肝经;消食健胃,行气散瘀。
薏苡仁:本品为禾本科植物薏苡的干燥成熟种仁;味甘、淡,性凉;归脾、胃、肺经;健脾渗湿,除痹止泻,清热排浓。
甘草:本品为豆科植物甘草、胀果甘草或光果甘草的干燥根;味甘,性平;归心、肺、脾、胃经;补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。
本发明中药组方的配伍分析:
本发明中药组方依据中医对湿疹的辨证认知,遵循中药的配伍理论,为了制成方便易用且疗效稳定的制剂,强化了药材的使用量。该组方是以荷叶、青皮和山楂为君药,清热解暑、消食健胃、行气散瘀;以鸡血藤、丹参、川芎、泽泻和厚朴为臣药,活血行气、下气除满、利小便;以三七、当归、枳壳和薏苡仁为佐药,润肠通便、行滞消胀、除烦止呕、健脾渗湿;以甘草为使药,调和诸药药性,诸药配合,相辅相成,协同作用,共奏利尿泄热、润肠通便、下气除满、消食健胃等功效,对肥胖症有十分显著的疗效。
与现有技术相比,本发明有益效果总结如下:
(1)本发明利用各种中药的综合作用治疗肥胖症,不仅能够健胃补脾、下气除满,利水利尿,而且还能有效降低甘油三酯、胆固醇和血糖,提高免疫力,强身健体。
(2)本发明中药制剂处方合理,補而不腻,消而不伤正,药性平和,配伍严谨,消補兼施。总之,本发明中药制剂用于治疗肥胖症成本低,制备方法简单、安全有效,毒副作用小,疗效稳定、确切。
具体实施方式
以下将通过具体实施例对本发明进行进一步描述,本领域技术人员应理解,本发明除以下实施例外还可做出其他类似的改变获得相似的结果而不脱离本发明的内容和精神范围。
实施例1
本发明实施例1中药制剂由如下重量配方的中药组成:
鸡血藤10、丹参10、青皮10、荷叶12、川芎10、泽泻10、厚朴8、三七8、当归8、枳壳6、山楂10、薏苡仁12和甘草2。
制备方法如下:
S1:取鸡血藤,洗去杂质,干燥后粉碎,过80目筛,加入药材总重量8倍量体积分数为80%的乙醇,再加入药材总量1.2%的纤维素酶,在45℃下浸提1小时,然后在95℃回流提取5小时,过滤并保留鸡血藤滤渣,滤液减压浓缩至60℃下相对密度为1.10的浸膏,制得鸡血藤提取物;
S2、分别称取丹参、青皮、荷叶、当归、枳壳、竹茹、山楂、薏苡仁和甘草,粉碎,混合,加入8倍药材重量的纯化水,煎煮3次,每次5小时,过滤,合并滤液,浓缩为原体积的1/4,获得提取液A,备用;
S3、分别称取三七、川芎、厚朴和泽泻,粉碎,混合,合并鸡血藤滤渣,加7倍药材重量90%的乙醇,回流提取3次,每次6小时,合并醇提液,减压蒸馏,除去乙醇,获得提取液B,备用;
S4、将鸡血藤提取物、提取液A和提取液B混合,浓缩至80℃时相对密度为1.25的中药浸膏,喷雾干燥,过100目筛,即得中药细粉;
S5、往上述中药细粉添加适当辅料,以现代中药制剂常规工艺制成胶囊剂。
实施例2
本发明实施例2中药制剂由如下重量配方的中药组成:
鸡血藤20、丹参24、青皮22、荷叶22、川芎20、泽泻22、厚朴16、三七14、当归12、枳壳12、山楂14、薏苡仁16和甘草10。
制备方法同实施例1。
实施例3
本发明实施例3中药制剂由如下重量配方的中药组成:
鸡血藤15、丹参18、青皮16、荷叶16、川芎14、泽泻16、厚朴12、三七10、当归10、枳壳10、山楂12、薏苡仁14和甘草6。
制备方法同实施例1。
药效学研究:
试验例一:本发明中药制剂对大鼠肥胖症的影响研究
1、实验方法
选取48只SPF级SD大鼠,体重100-120g,8-10周龄,其中40只给予含有高脂肪高热量的自制饲料。所有大鼠均自由饮水、进食,光照周期为昼夜各半,室温20-24℃。每周一测量并记录体重。14周后,给予高能饲料的大鼠中体重超过给予标准动物饲料大鼠平均体重的120%,则达到肥胖标准,高脂饮食肥胖模型建立成功。另外8只同等条件下给予标准动物饲料,设为正常对照组。
将建立好的高脂饮食肥胖模型鼠40只随机分为5组,每组8只,分别为本发明实施例1中药胶囊的高、中、低剂量组、阳性对照组和模型组。高、中、低剂量组分别给予40mg/Kg、20mg/Kg、10mg/Kg药物剂量处理,给药方式为灌胃给药,每天2次,连续用药20天;阳性对照组给予40mg/Kg奥利司他(杭州中美华东制药有限公司);模型组和正常对照组均采用等容积生理盐水处理,给药方式同给药组。用药20天后,将大鼠迅速用特制铡刀断头,每只大鼠取血4ml,加入预先加好40U肝素的离心管中,4℃、3000r.p.m转速离心20分钟,取上清测定血浆胆固醇、甘油三酯和血糖浓度。标本采集在试验期间,每周称量体重一次。给药期间各组小鼠都给予标准动物饲料。
2、数据处理
数据均采用均数±标准差表示,采用SPSS19.0统计软件进行方差分析,P<0.05为有显著性差异;P<0.01为有极显著差异。
3、实验结果
如表1所示。
表1各组大鼠体重、胆固醇、甘油三酯和血糖水平
注:“+”表示增重;“-”表示减重;与正常对照组比较,△△ P<0.01,△△△ P<0.001;与模型组比较,* P<0.05,** P<0.01,*** P<0.001;与阳性对照组比较,# P<0.05,## P<0.01。
由上表1可知,与正常对照组比较,模型组大鼠的体重、胆固醇、甘油三酯和血糖水平极显著增加(P<0.01),说明高脂饮食肥胖模型构建成功。给药后,本发明中药制剂高、中、低剂量组和阳性对照组的大鼠体重均大大减轻,各组大鼠的胆固醇、甘油三酯和血糖水平与模型组相比,显著降低(P<0.05),其中本发明中药制剂高剂量组治疗效果显著优于阳性对照组(P<0.05或P<0.01)。由此可知,本发明中药制剂的三个剂量组均可显著降低大鼠体重、胆固醇、甘油三酯和血糖水平,具有良好的治疗肥胖症的效果。
试验二:本发明中药制剂对肥胖症志愿者患者的临床疗效观察
一、病例及诊断标准
1、西医诊断标准:
根据《亚太地区肥胖及其治疗的重新定义》有关肥胖症诊断标准拟定::
(1)体重超过标准体重的20%-30%或BMI在26-30为轻度肥胖;
(2)体重超过标准体重的30%-50%或BMI在30-40为中度肥胖;
(3)体重超过标准体重50%以上或BMI大于40为重度肥胖。
2、中医诊断标准:
按照单纯性肥胖症中医辨证分型为脾虚湿阻、胃热湿阻、肝郁气滞、脾肾阳虚、阴虚内热共五型,具体表现如下:
(1)脾虚湿阻——形体肥胖,肌肉松他,伴神疲乏力,肢体困重,纳呆便溏,小便量少,舌胖笞腻,脉沉细无力。
(2)胃热湿阻——形体肥胖,消谷善饥,口臭难闻,渴喜冷饮,伴头胀头晕,肢体沉重,懒于动作,小便黄,大便干结,舌红苔黄腻,脉滑数。
(3)肝郁气滞——形体肥胖臃肿,胸胁苦满,急躁易怒,失眠多梦,多饮多食,口苦咽千,妇女可见乳房胀痛或小腹胀痛,月经不调或闭经,舌红苔薄白,脉弦。
(4)脾肾阳虚——形体肥胖,神疲乏力,形寒肢冷,腰酸腿软,阳痿早泄,宫冷不孕,大便溏稀,小便清长,脉沉细无力,苔白,舌质淡红。
(5)阴虚内热——形体肥胖,头昏眼花,头胀头痛,五心烦热,腰痛酸软,脉细数微弦,舌苔薄、舌尖红。
二、临床试验
1、一般资料
筛选320例符合上述诊断标准的肥胖症临床志愿患者,年龄为10-55岁,平均年龄35岁,男女各半。随机分为治疗A组、治疗B组、治疗C组和对照组,每组80人,四组患者年龄、症状等影响因素,经统计学处理,无显著性差异,符合分组条件。
2、治疗方法
治疗A组:服用本发明实施例1所制胶囊,每次2颗,每天1次,连用30天。
治疗B组:服用本发明实施例2所制胶囊,给药方案同治疗A组。
治疗C组:服用本发明实施例3所制胶囊,给药方案同治疗A组。
对照组:服用奥利司他(重庆鼎联制药有限公司生产),每次2片,每天1次,连用30天。
3、临床疗效评价标准
治疗单纯性肥胖的疗效标准,即:
(1)临床治愈:体重指数下降到26以下,相关症状消失;
(2)显效:体重指数下降大于等于4,相关症状基本消失;
(3)有效:体重指数下降大于等于2,相关症状减轻;
(4)无效:体重指数下降值不到2,相关症状未减轻。
4、治疗结果
表2治疗效果
5、结论
从临床治愈率和总有效率可知,本发明实施例中药制剂临床治愈率均大于50%,总有效率大于90%,远高于对照组的临床痊愈率和总有效率,其中以治疗A组即实施例1的效果最佳。由此可见,本发明的中药制剂相对于西药,治疗肥胖症具有显著的疗效。所有受试者经体格检查,血、尿常规、心电图、肝肾功能等安全性检查,进一步证实本发明用于治疗肥胖症安全有效,具有推广应用的价值。
Claims (7)
1.一种治疗肥胖症的中药制剂,其特征在于,所述中药制剂的中药组方由下述重量配方的中药制备而成:
鸡血藤10-20、丹参10-24、青皮10-22、荷叶12-22、10-20、泽泻10-22、厚朴8-16、三七8-14、当归8-12、枳壳6-12、山楂10-14、薏苡仁12-16和甘草2-10。
2.根据权利要求1所述的治疗肥胖症的中药制剂,其特征在于,所述中药制剂的中药组方中各药材重量配方为:
鸡血藤10、丹参10、青皮10、荷叶12、川芎10、泽泻10、厚朴8、三七8、当归8、枳壳6、山楂10、薏苡仁12和甘草2。
3.根据权利要求1所述的治疗肥胖症的中药制剂,其特征在于,所述中药制剂的中药组方中各药材重量配方为:
鸡血藤20、丹参24、青皮22、荷叶22、川芎20、泽泻22、厚朴16、三七14、当归12、枳壳12、山楂14、薏苡仁16和甘草10。
4.根据权利要求1所述的治疗肥胖症的中药制剂,其特征在于,所述中药制剂的中药组方中各药材重量配方为:
鸡血藤15、丹参18、青皮16、荷叶16、川芎14、泽泻16、厚朴12、三七10、当归10、枳壳10、山楂12、薏苡仁14和甘草6。
5.根据权利要求1-4任一所述的治疗肥胖症的中药制剂,其特征在于,所述中药制剂的制备方法包括以下步骤:
S1:取鸡血藤,洗去杂质,干燥后粉碎,过80-100目筛,加入药材总重量8-10倍量体积分数为60-80%的乙醇,再加入药材总量0.8-1.2%的纤维素酶,在38-45℃下浸提1-2小时,然后在85-95℃回流提取3-5小时,过滤并保留鸡血藤滤渣,滤液减压浓缩至60℃下相对密度为1.10-1.25的浸膏,制得鸡血藤提取物;
S2、分别称取丹参、青皮、荷叶、当归、枳壳、竹茹、山楂、薏苡仁和甘草,粉碎,混合,加入8-11倍药材重量的纯化水,煎煮2-3次,每次3-5小时,过滤,合并滤液,浓缩为原体积的1/6-1/4,获得提取液A,备用;
S3、分别称取三七、川芎、厚朴和泽泻,粉碎,混合,合并鸡血藤滤渣,加4-7倍药材重量70-90%的乙醇,回流提取2-3次,每次3-6小时,合并醇提液,减压蒸馏,除去乙醇,获得提取液B,备用;
S4、将鸡血藤提取物、提取液A和提取液B混合,浓缩至70-80℃时相对密度为1.25-1.36的中药浸膏,喷雾干燥,过100-200目筛,即得。
6.根据权利要求1-4任一所述的治疗肥胖症的中药制剂,其特征在于,所述中药制剂为颗粒剂、片剂、胶囊剂、丸剂、口服液和散剂。
7.根据权利要求1-4任一所述的治疗肥胖症的中药制剂的制备方法,其特征在于,包括以下步骤:
S1:取鸡血藤,洗去杂质,干燥后粉碎,过80-100目筛,加入药材总重量8-10倍量体积分数为60-80%的乙醇,再加入药材总量0.8-1.2%的纤维素酶,在38-45℃下浸提1-2小时,然后在85-95℃回流提取3-5小时,过滤并保留鸡血藤滤渣,滤液减压浓缩至60℃下相对密度为1.10-1.25的浸膏,制得鸡血藤提取物;
S2、分别称取丹参、青皮、荷叶、当归、枳壳、竹茹、山楂、薏苡仁和甘草,粉碎,混合,加入8-11倍药材重量的纯化水,煎煮2-3次,每次3-5小时,过滤,合并滤液,浓缩为原体积的1/6-1/4,获得提取液A,备用;
S3、分别称取三七、川芎、厚朴和泽泻,粉碎,混合,合并鸡血藤滤渣,加4-7倍药材重量70-90%的乙醇,回流提取2-3次,每次3-6小时,合并醇提液,减压蒸馏,除去乙醇,获得提取液B,备用;
S4、将鸡血藤提取物、提取液A和提取液B混合,浓缩至70-80℃时相对密度为1.25-1.36的中药浸膏,喷雾干燥,过100-200目筛,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510904037.1A CN105343675A (zh) | 2015-12-09 | 2015-12-09 | 一种治疗肥胖症的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510904037.1A CN105343675A (zh) | 2015-12-09 | 2015-12-09 | 一种治疗肥胖症的中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105343675A true CN105343675A (zh) | 2016-02-24 |
Family
ID=55319834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510904037.1A Withdrawn CN105343675A (zh) | 2015-12-09 | 2015-12-09 | 一种治疗肥胖症的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105343675A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109893643A (zh) * | 2019-03-19 | 2019-06-18 | 南京星银药业集团有限公司 | 一种治疗肥胖症的组合物及其制备方法 |
CN114306560A (zh) * | 2021-12-21 | 2022-04-12 | 安徽华大医药科技有限公司 | 一种用于治疗肥胖及心肌性疾病的中药组合物的研制 |
-
2015
- 2015-12-09 CN CN201510904037.1A patent/CN105343675A/zh not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109893643A (zh) * | 2019-03-19 | 2019-06-18 | 南京星银药业集团有限公司 | 一种治疗肥胖症的组合物及其制备方法 |
CN114306560A (zh) * | 2021-12-21 | 2022-04-12 | 安徽华大医药科技有限公司 | 一种用于治疗肥胖及心肌性疾病的中药组合物的研制 |
CN114306560B (zh) * | 2021-12-21 | 2023-09-08 | 深圳前海禾美未来生物科技有限公司 | 一种治疗肥胖的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104127699A (zh) | 益元养生制剂及其制备方法 | |
CN106421649A (zh) | 一种治疗脑中风的中药组合物及其制备方法 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN104887747A (zh) | 一种治疗脑血栓的中药组合物及其制备方法 | |
CN104225166A (zh) | 一种治疗闭经的中药组合物及其制备方法 | |
CN104491236A (zh) | 一种治疗原发性高血压的中药制剂及其制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
CN105343808A (zh) | 一种具有减肥效果的中药组合物及其制备方法 | |
CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN101961448A (zh) | 一种治疗糖尿病痛风的中药 | |
CN104888133A (zh) | 一种治疗冠心病的中药组合物 | |
CN104800610A (zh) | 一种治疗帕金森病的中药制剂及其制备方法 | |
CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
CN105497783A (zh) | 一种中药制剂在制备治疗气滞血瘀型黄褐斑药物中的用途 | |
CN104623061B (zh) | 一种抗疲劳药 | |
CN104491602A (zh) | 一种治疗慢性心衰、早搏、心律失常的中药及其制备方法 | |
CN105497521A (zh) | 一种制备治疗少精不育症的中药制剂的方法 | |
CN105412824A (zh) | 一种治疗肥胖症的药物组合物 | |
CN105396062A (zh) | 一种制备治疗肥胖症的药物组合物的方法 | |
CN105434979A (zh) | 一种含有艾叶的治疗肥胖症的中药制剂及其制备方法 | |
CN104645247A (zh) | 一种治疗肝豆状核变性的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160224 |
|
WW01 | Invention patent application withdrawn after publication |